High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein

Journal of Autoimmunity

Volumn 34, Issue 2, 2010, Pages 121-126

  Novick, Daniela ^a   Elbirt, Daniel ^b   Miller, Galit ^b   Dinarello, Charles A ^c   Rubinstein, Menachem ^a   Sthoeger, Zev M ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Active SLE; Cytokines; Free IL 18; IFN ; IL 18BP

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG SYNTHESIS; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; CHILD; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 75349084506     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.08.002     Document Type: Article

References (62)

1. Rahman A., and Isenberg D.A. Systemic lupus erythematosus. The New England Journal of Medicine 358 (2008) 929-939
2. Sthoeger Z.M., Chiorazzi N., and Lahita R.G. Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. Journal of Immunology 141 (1988) 91-98
3. Sullivan K.E. Genetics of systemic lupus erythematosus. Clinical implications. Rheumatic Diseases Clinics of North America 26 (2000) 229-256 [v-vi]
4. James J.A., Kaufman K.M., Farris A.D., Taylor-Albert E., Lehman T.J., and Harley J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. The Journal of Clinical Investigation 100 (1997) 3019-3026
5. Jonsen A., Bengtsson A.A., Nived O., Truedsson L., and Sturfelt G. Gene-environment interactions in the aetiology of systemic lupus erythematosus. Autoimmunity 40 (2007) 613-617
6. Lu L., Kaliyaperumal A., Boumpas D.T., and Datta S.K. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. The Journal of Clinical Investigation 104 (1999) 345-355
7. Isenberg D.A., Manson J.J., Ehrenstein M.R., and Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. Rheumatology (Oxford, England) 46 (2007) 1052-1056
8. Nagy G., Koncz A., and Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Critical Reviews in Immunology 25 (2005) 123-140
9. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. Journal of Immunology 152 (1994) 3685-3692
10. Valencia X., Yarboro C., Illei G., and Lipsky P.E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. Journal of Immunology 178 (2007) 2579-2588
11. Horwitz D.A., and Jacob C.O. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Seminars in Immunopathology 16 (1994) 181-200
12. Segal R., Bermas B.L., Dayan M., Kalush F., Shearer G.M., and Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. Journal of Immunology 158 (1997) 3009-3016
13. Sthoeger Z.M., Sharabi A., Dayan M., Zinger H., Asher I., Sela U., et al. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Human Immunology 70 (2009) 139-145
14. Kono D.H., and Theofilopoulos A.N. Genetics of SLE in mice. Springer Seminars in Immunopathology 28 (2006) 83-96
15. Ardoin S.P., and Pisetsky D.S. Developments in the scientific understanding of lupus. Arthritis Research & Therapy 10 (2008) 218
16. Aringer M., and Crow M.K. A bridge between interferon-alpha and tumor necrosis factor in lupus. The Journal of Rheumatology 35 (2008) 1473-1476
17. Blanco P., Palucka A.K., Gill M., Pascual V., and Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (New York, NY) 294 (2001) 1540-1543
18. Crow M.K. Type I interferon in systemic lupus erythematosus. Current Topics in Microbiology and Immunology 316 (2007) 359-386
19. Garrett-Sinha L.A., John S., and Gaffen S.L. IL-17 and the Th17 lineage in systemic lupus erythematosus. Current Opinion in Rheumatology 20 (2008) 519-525
20. Dean G.S., Tyrrell-Price J., Crawley E., and Isenberg D.A. Cytokines and systemic lupus erythematosus. Annals of the Rheumatic Diseases 59 (2000) 243-251
21. Luger D., Dayan M., Zinger H., Liu J.P., and Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. Journal of Clinical Immunology 24 (2004) 579-590
22. Peng S.L., Moslehi J., and Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. The Journal of Clinical Investigation 99 (1997) 1936-1946
23. Nicoletti F., Di Marco R., Zaccone P., Xiang M., Magro G., Grasso S., et al. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. European Journal of Immunology 30 (2000) 438-447
24. Graninger W.B., Hassfeld W., Pesau B.B., Machold K.P., Zielinski C.C., and Smolen J.S. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. The Journal of Rheumatology 18 (1991) 1621-1622
25. Esfandiari E., McInnes I.B., Lindop G., Huang F.P., Field M., Komai-Koma M., et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. Journal of Immunology 167 (2001) 5338-5347
26. Bossu P., Neumann D., Del Giudice E., Ciaramella A., Gloaguen I., Fantuzzi G., et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 14181-14186
27. Neumann D., Del Giudice E., Ciaramella A., Boraschi D., and Bossu P. Lymphocytes from autoimmune MRL lpr/lpr mice are hyperresponsive to IL-18 and overexpress the IL-18 receptor accessory chain. Journal of Immunology 166 (2001) 3757-3762
28. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 (1995) 88-91
29. Okamura H., Kashiwamura S., Tsutsui H., Yoshimoto T., and Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Current Opinion in Immunology 10 (1998) 259-264
30. Aringer M., and Smolen J.S. Cytokine expression in lupus kidneys. Lupus 14 (2005) 13-18
31. Boraschi D., and Dinarello C.A. IL-18 in autoimmunity: review. European Cytokine Network 17 (2006) 224-252
32. Wang D., Drenker M., Eiz-Vesper B., Werfel T., and Wittmann M. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis and Rheumatism 58 (2008) 3205-3215
33. Novick D., Kim S.H., Fantuzzi G., Reznikov L.L., Dinarello C.A., and Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999) 127-136
34. Kim S.H., Eisenstein M., Reznikov L., Fantuzzi G., Novick D., Rubinstein M., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 1190-1195
35. Hurgin V., Novick D., and Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 16957-16962
36. Xu Q., Tin S.K., Sivalingam S.P., Thumboo J., Koh D.R., and Fong K.Y. Interleukin-18 promoter gene polymorphisms in Chinese patients with systemic lupus erythematosus: association with CC genotype at position-607. Annals of the Academy of Medicine, Singapore 36 (2007) 91-95
37. Lin Y.J., Wan L., Sheu J.J., Huang C.M., Lin C.W., Lan Y.C., et al. A/C polymorphism in the interleukin-18 coding region among Taiwanese systemic lupus erythematosus patients. Lupus 17 (2008) 124-127
38. Sánchez E., Palomino-Morales R.J., Ortego-Centeno N., Jiménez-Alonso J., González-Gay M.A., López-Nevot M.A., et al. Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. Human Molecular Genetics (2009 Jul 7) [Epub ahead of print]
39. Novick D., Elbirt D., Dinarello C.A., Rubinstein M., and Sthoeger Z.M. Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis. Journal of Clinical Immunology 29 (2009) 38-45
40. Wong C.K., Li E.K., Ho C.Y., and Lam C.W. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford, England) 39 (2000) 1078-1081
41. Lee H.T., Chen W.S., Sun K.H., Chou C.T., and Tsai C.Y. Increased spontaneous but decreased mitogen-stimulated expression and excretion of interleukin 18 by mononuclear cells in patients with active systemic lupus erythematosus. The Journal of Rheumatology (2009 Jul 15) [Epub ahead of print]
42. Novick D., Schwartsburd B., Pinkus R., Suissa D., Belzer I., Sthoeger Z., et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14 (2001) 334-342
43. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., and Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. European Cytokine Network 16 (2005) 27-33
44. Leach S.T., Messina I., Lemberg D.A., Novick D., Rubenstein M., and Day A.S. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflammatory Bowel Disease 14 (2008) 68-74
45. Wong C.K., Ho C.Y., Li E.K., Tam L.S., and Lam C.W. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clinical and Experimental Immunology 130 (2002) 345-351
46. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 25 (1982) 1271-1277
47. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis and Rheumatism 35 (1992) 630-640
48. Gatto-Menking D.L., Yu H., Bruno J.G., Goode M.T., Miller M., and Zulich A.W. Sensitive detection of biotoxoids and bacterial spores using an immunomagnetic electrochemiluminescence sensor. Biosensors and Bioelectronics 10 (1995) 501-507
49. Puren A.J., Fantuzzi G., Gu Y., Su M.S., and Dinarello C.A. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. The Journal of Clinical Investigation 101 (1998) 711-721
50. Tucci M., Quatraro C., Lombardi L., Pellegrino C., Dammacco F., and Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis and Rheumatism 58 (2008) 251-262
51. Kaser A., Novick D., Rubinstein M., Siegmund B., Enrich B., Koch R.O., et al. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clinical and Experimental Immunology 129 (2002) 332-338
52. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106 (2005) 3483-3489
53. Harigai M., Kawamoto M., Hara M., Kubota T., Kamatani N., and Miyasaka N. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. Journal of Immunology 181 (2008) 2211-2219
54. Eisenberg R. Why can't we find a new treatment for SLE?. Journal of Autoimmunity 32 (2009) 223-230
55. Ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 121 (2001) 1372-1379
56. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K., Born T.L., Derry J.M., et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50 (2002) 812-820
57. Zaccone P., Phillips J., Conget I., Cooke A., and Nicoletti F. IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse. Clinical Immunology 115 (2005) 74-79
58. Plitz T., Saint-Mézard P., Satho M., Herren S., Waltzinger C., de Carvalho Bittencourt M., et al. IL-18 binding protein protects against contact hypersensitivity. Journal of Immunology 171 (2003) 1164-1171
59. He Z., Lu L., Altmann C., Hoke T.S., Ljubanovic D., Jani A., et al. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. American Journal of Physiology - Renal Physiology 295 (2008) F1414-F1421
60. Wu H., Craft M.L., Wang P., Wyburn K.R., Chen G., Ma J., et al. IL-18 contributes to renal damage after ischemia-reperfusion. Journal of the American Society of Nephrology 19 (2008) 2331-2341
61. Mallat Z., Corbaz A., Scoazec A., Graber P., Alouani S., Esposito B., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circulation Research 89 (2001) E41-E45
62. Li J.M., Eslami M.H., Rohrer M.J., Dargon P., Joris I., Hendricks G., et al. Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model. Journal of Vascular Surgery 47 (2008) 1048-1057